Sarepta (SRPT) Pops Higher as Glaxo's DMD Drug Drisapersen Falters
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Up)Join SI Premium – FREE
Sarepta Therapeutics (Nasdaq: SRPT) shares are active Wednesday afternoon following speculation that it might be able to pick up where GlaxoSmithKline (NYSE: GSK) is leaving off.
Biotech stock watcher Adam Feuerstein commented today that duchenne muscular dystrophy (DMD) patients trated with Glaxo's drisapersen are said to have been hospitalized due to kidney toxicity and low platelet counts.
Though the announcement was made last Sunday during a medical meeting in Rome, Feuerstein speculates that Sarepta might be meeting with FDA reps over the possibility of accelerating the approval of the company's DMD drug eteplirsen "based on a completed phase II study." Eteplirsen's record to-date has been relatively sterling.
Shares of Sarepta are up 7.5 percent on heavy volume today. The stock is a bit of a favorite with short sellers, as 3.84 million shares, or 14.5 percent of float, are currently being held short.
Biotech stock watcher Adam Feuerstein commented today that duchenne muscular dystrophy (DMD) patients trated with Glaxo's drisapersen are said to have been hospitalized due to kidney toxicity and low platelet counts.
Though the announcement was made last Sunday during a medical meeting in Rome, Feuerstein speculates that Sarepta might be meeting with FDA reps over the possibility of accelerating the approval of the company's DMD drug eteplirsen "based on a completed phase II study." Eteplirsen's record to-date has been relatively sterling.
Shares of Sarepta are up 7.5 percent on heavy volume today. The stock is a bit of a favorite with short sellers, as 3.84 million shares, or 14.5 percent of float, are currently being held short.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
